Advertisement

 

 

Kallistatin levels in HIV-infected patients and effects of statin therapy.

Kallistatin levels in HIV-infected patients and effects of statin therapy.
Author Information (click to view)

Eckard AR, Cho S, O'Riordan MA, McComsey GA,


Eckard AR, Cho S, O'Riordan MA, McComsey GA, (click to view)

Eckard AR, Cho S, O'Riordan MA, McComsey GA,

Advertisement
Share on FacebookTweet about this on TwitterShare on LinkedIn

Biomarkers : biochemical indicators of exposure, response, and susceptibility to chemicals 2016 9 20() 1-8

Abstract
BACKGROUND
Kallistatin, a serine proteinase inhibitor, has vasodilatory and anti-inflammatory properties and is increased in other inflammatory conditions. We measured kallistatin in HIV for the first time, examined its relationship with inflammation, and determined if statin therapy affected levels.

METHODS
Kallistatin levels were measured in subjects from a randomized, double-blinded, placebo-controlled trial.

RESULTS
One hundred and thirty-five HIV-infected subjects were included. Kallistatin levels were 28.4 μg/mL at baseline and not affected by rosuvastatin. Levels were correlated with high-sensitivity C-reactive protein (hsCRP), interleukin-6, fibrinogen and insulin resistance.

CONCLUSIONS
Kallistatin levels were correlated with some markers of systemic inflammation and should be further explored in the HIV population.

Submit a Comment

Your email address will not be published. Required fields are marked *

1 × 5 =

[ HIDE/SHOW ]